imnn-001
Gene therapyexperimental
Clinical trial activity
1 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Feb 10, 2023 (NCT05739981)
Timeline
2020s
- Jan 1, 2023
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Interleukin-12 subunit betaSupplementation
IL12B supplementation
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05739981 | Phase 1/Phase 2 (Phase 2) | Feb 10, 2023 | Breakthrough Cancer Research, Celsion, University of Texas at Houston |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Breakthrough Cancer Research | Academic/Hospital | 1 | 0 | 1 | 2023 |
| Celsion | For profit | 1 | 1 | 1 | 2023 |
| University of Texas at Houston | Academic/Hospital | 1 | 0 | 1 | 2023 |
3 organizations
Page 1 / 1